The Category and Its Construction
The word schizophrenia was coined by Eugen Bleuler on April 24, 1908, at a meeting of the German Psychiatric Association in Berlin, as a replacement for Emil Kraepelin’s earlier designation dementia praecox — premature dementia. Bleuler’s objection was precise: the condition involved neither dementia in the classical sense nor any necessary early onset, and the name Kraepelin had given it encoded two empirical claims the evidence did not support. The replacement term, from the Greek schizein (to split) and phrēn (mind), was intended to name what Bleuler considered the core feature: a splitting of the psychic functions — affect from cognition, volition from perception, the inner world from the outer.
Kraepelin had consolidated the category in the sixth edition of his Psychiatrie textbook in 1899, drawing together catatonia (Kahlbaum, 1874), hebephrenia (Hecker, 1871), and paranoid presentations into a single disease entity distinguished from manic-depressive insanity by its presumed chronic deteriorating course. The Kraepelinian dichotomy — schizophrenia on one side, bipolar disorder on the other — remains the load-bearing partition in psychiatric nosology to this day, despite over a century of failed attempts to identify the biological substrate that would justify treating the two as categorically distinct diseases rather than as overlapping regions of a continuous phenomenological space.
The diagnostic criteria have been rewritten in every edition of the DSM. The DSM-I (1952) described a “schizophrenic reaction” in the Meyerian psychobiological framing. The DSM-III (1980), under Robert Spitzer, introduced the nominally atheoretical descriptive-symptom approach and elevated Kurt Schneider’s first-rank symptoms — auditory hallucinations, thought insertion, delusions of control — to near-pathognomonic status. The DSM-5 (2013) eliminated the classical subtypes (paranoid, catatonic, disorganized, undifferentiated, residual) entirely and removed the special status of first-rank symptoms, collapsing the category into a single polythetic diagnosis requiring two of five symptom clusters. Across six editions the category has been built, dismantled, and rebuilt without the underlying biological entity having been identified. The diagnostic concept of schizophrenia, as Jablensky observed in Dialogues in Clinical Neuroscience (2010), remains “a construct of uncertain validity” — no pathognomonic symptom, no laboratory test, no biological marker despite a century of intensive research.
What has remained constant is the phenomenology the category captures: auditory hallucinations (particularly voices), paranoid ideation, thought disorder, flattened or incongruent affect, social withdrawal, and in acute episodes a dissolution of the ordinary boundaries between self and world that the experiencer cannot control or contextualize. This phenomenology is real, is cross-culturally documented, and produces genuine suffering. The question the category forecloses is whether the phenomenology is best understood as the output of a broken brain, or whether at least some fraction of it represents the output of a nervous system undergoing a process that older frameworks recognized and handled differently.
The Dopamine Hypothesis and Its Revisions
The biological anchor of the standard treatment model is the dopamine hypothesis, which has undergone three major revisions without producing a confirmed etiology. Version I (1960s–1970s) proposed simple dopamine excess, derived from the observation that antipsychotic potency correlates linearly with D2 receptor binding affinity — a correlation established by Seeman and Lee in Science (1975) and Creese et al. (1976). Version II (Davis et al., American Journal of Psychiatry, 1991) proposed subcortical hyperdopaminergia alongside prefrontal hypodopaminergia, accounting for both positive and negative symptoms.
Version III, formalized by Howes and Kapur in Schizophrenia Bulletin (2009), locates the primary dysfunction at presynaptic striatal dopamine synthesis capacity — elevated in seven of nine PET studies — rather than at postsynaptic receptor density. The mechanism proposed is aberrant salience: inappropriate motivational significance assigned to neutral stimuli, which the individual then attempts to explain, producing the delusional and hallucinatory content. The revision carries a critical internal admission: current antipsychotics act downstream of the primary abnormality by blocking postsynaptic D2 receptors, and may paradoxically worsen presynaptic function by blocking autoreceptors and triggering compensatory synthesis increases. Howes and Kapur themselves acknowledge that Version III is “more accurately a dopamine hypothesis of psychosis-in-schizophrenia” — the hypothesis does not explain negative symptoms, cognitive deficits, or the thirty to forty percent of patients who remain treatment-resistant to D2 blockade.
The supersensitivity psychosis problem, first described by Chouinard and Jones (American Journal of Psychiatry, 1978), follows from this mechanism: chronic D2 blockade produces compensatory receptor upregulation, so that when medication is reduced or discontinued, endogenous dopamine acting on the expanded receptor pool produces psychosis more severe than the original condition. A fraction of what the clinical literature classifies as “relapse” is withdrawal-emergent supersensitivity psychosis — an iatrogenic condition produced by the treatment itself. The chronification trap operates through circular confirmation: discontinuation produces worse symptoms, apparently confirming the need for continued medication, while the worsening is itself evidence that the medication has produced pharmacological dependence through receptor remodeling. Yin et al. (2017) proposed formal diagnostic criteria for antipsychotic-induced supersensitivity psychosis in Pharmacopsychiatry, indicating that the phenomenon is now acknowledged within the clinical literature even if the standard-of-care prescribing protocols have not incorporated the implication.
The 2024 FDA approval of xanomeline/trospium (Cobenfy) — the first non-dopaminergic mechanism approved for schizophrenia in seventy years — constitutes a practical challenge to the dopamine-centric framework. The drug acts through muscarinic acetylcholine receptors rather than D2 blockade, and its efficacy in patients who respond poorly to conventional antipsychotics suggests that the “final common pathway” may be wider than Version III proposes.
Brain Volume Loss and the Treatment Paradox
The most consequential neuroimaging finding in the schizophrenia literature appeared in Ho et al. (Archives of General Psychiatry, 2011): a longitudinal study of 211 patients with 674 high-resolution MRI scans across a mean follow-up of 7.2 years. The Iowa Longitudinal Study found that greater antipsychotic dose predicted smaller gray matter volumes — total cerebral, frontal, temporal, and parietal — independent of illness severity, substance use, and illness duration. Patients in the highest dose tertile showed white matter reductions; patients in the lowest dose tertile showed white matter increases consistent with normal aging. The authors’ conclusion was explicit: “although antipsychotics relieve psychosis and its attendant suffering, these drugs may not arrest the pathophysiologic processes underlying schizophrenia and may even aggravate progressive brain tissue volume reductions.”
Dorph-Petersen et al. (2005, Neuropsychopharmacology) had provided the animal validation: macaques receiving haloperidol and olanzapine at therapeutic plasma levels for seventeen to twenty-seven months showed eight to eleven percent decreases in fresh brain weight and volume compared to sham-treated controls. The mechanism involved decreased astrocyte numbers and dendritic arborization, with no neuronal loss — the drugs were not killing neurons but were shrinking the connectivity architecture.
Prior to these studies, the dominant narrative attributed brain volume loss in schizophrenia patients to the disease process itself. The Ho et al. finding reframed the question: once illness severity and duration are controlled, medication dosage is the stronger predictor of brain tissue loss. The finding has not been refuted. It has been contested on confounding grounds and has not modified the standard-of-care prescribing model.
The Shamanic Parallel
The ethnographic record is unambiguous on one point: every documented shamanic tradition describes an initiatory crisis whose phenomenology overlaps substantially with what the DSM classifies as schizophrenia. The candidate shaman hears voices, sees beings invisible to others, withdraws from social functioning, loses contact with consensus reality, and in many cases experiences dismemberment, death, and reassembly in visionary space. The crisis is involuntary — the candidate does not choose it — and the community’s response is to place the candidate in the care of an experienced shaman who recognizes the process, provides a framework for understanding it, and guides it toward resolution. The candidate who survives the initiatory crisis and integrates the experience emerges as a healer, a mediator between worlds, and a functionary of considerable social value. Mircea Eliade’s Shamanism (1951) and Ioan Lewis’s Ecstatic Religion (1971) document this pattern across cultures and continents.
Julian Silverman’s 1967 paper “Shamans and Acute Schizophrenia” in American Anthropologist made the structural comparison explicit. Silverman, working at the National Institute of Mental Health, argued that the difference between the shaman and the acute schizophrenic was not in the underlying psychological process but in the social response. The shaman’s culture provides a cognitive framework, an experienced guide, and a defined social role that channels the process toward integration. The Western psychiatric patient receives no framework, no guide who recognizes the process, and a social role — patient — that defines the experience as pathological. The process that produces a healer in one context produces a chronic patient in the other, and the variable that differs is not the biology but the cultural container.
John Weir Perry, a Jungian analyst who trained at the C. G. Jung Institute in Zurich, spent decades working with acute psychotic patients and concluded that the content of acute psychotic episodes displayed a remarkable archetypal consistency. In The Far Side of Madness (1974) and Trials of the Visionary Mind (1999), Perry documented that patients in acute psychotic states spontaneously produced imagery — death and rebirth, world destruction and renewal, sacred marriage, encounter with divine or demonic figures — that mapped onto the mythological motifs Jung had identified as universal. Perry established Diabasis, an NIMH-supported residential facility in San Francisco circa 1974, where acute psychotic patients were cared for without neuroleptic medication, with staff trained to engage with the content of the psychotic experience rather than suppress it. Perry reported resolution of acute episodes within six to twelve weeks with return to functioning comparable to drug-treated populations. The facility closed around 1980 when NIMH withdrew support.
Bentov, Sannella, and the Physio-Kundalini Hypothesis
Itzhak Bentov, approaching the question from biomedical engineering rather than from clinical psychiatry, proposed a specific neurological mechanism that connected kundalini awakening to what psychiatry classifies as psychosis. His model, developed in Stalking the Wild Pendulum (1977), described the body in deep meditation as a coupled oscillator system in which cardiac-generated standing waves stimulate the sensory cortex in a sequence matching the cortical homunculus — beginning at the representation of the feet and legs and ascending through the torso to the crown. The resulting sensory cascade produces precisely the sequence of experiences classical kundalini literature describes: heat at the base of the spine, energy ascending through the body, involuntary movements, perceptual shifts, and at the extremes a complete dissolution of ordinary self-world boundaries.
Bentov’s clinical insight was that this same mechanism, when activated spontaneously in an unprepared nervous system, produces a symptom profile that psychiatric medicine has no framework to distinguish from acute psychosis. The person experiencing spontaneous kundalini activation presents with altered perception, involuntary movements, intense affect, disrupted sleep, and in some cases auditory and visual phenomena. These presentations map directly onto DSM criteria for schizophrenia-spectrum disorders, and the standard clinical response — antipsychotic medication — suppresses the coherence cascade by dampening neural conductivity. The immediate crisis resolves. The underlying process is aborted.
Lee Sannella, a San Francisco ophthalmologist and psychiatrist who collaborated with Bentov, formalized the clinical distinction in Kundalini: Psychosis or Transcendence? (H.S. Dakin, 1976; expanded edition, Integral Publishing, 1987). Sannella documented seventy-six cases in which individuals presenting with symptoms resembling acute psychosis were experiencing what he identified as kundalini activation on the basis of the characteristic sensory-motor sequence Bentov had described. His central argument was that the differential diagnosis mattered: a kundalini process supported through grounding, rest, and experienced guidance tends toward integration and enhanced functioning, while the same process suppressed by antipsychotics tends toward chronicity and diminished functioning.
Bruce Greyson, at the University of Virginia’s Division of Perceptual Studies, operationalized the distinction in his 1993 Journal of Transpersonal Psychology paper “The Physio-Kundalini Syndrome and Mental Illness.” Greyson developed the nineteen-item Physio-Kundalini Syndrome Index based on Bentov’s model and administered it to psychiatric inpatients, near-death experiencers, and controls. Both clinical groups showed elevated PKSI scores relative to controls; near-death experiencers showed more coherent sequential progression while psychiatric patients showed more fragmented and distressing presentations. The clinical markers that distinguish the two populations — preserved ego integrity, characteristic ascending somatic sequence, absence of negative symptoms, identifiable precipitant, maintained meta-awareness — are precisely the markers the standard diagnostic system does not assess. The DSM-IV (1994) introduced V-code 62.89, “Religious or Spiritual Problem,” advocated by Lukoff, Lu, and Turner (Journal of Nervous and Mental Disease, 1992) and grounded explicitly in Grof’s spiritual emergency concept — a non-pathologizing code that permits clinical documentation without a psychotic disorder diagnosis. The code exists. Its use in emergency psychiatric settings, where the triage decision between antipsychotic administration and watchful integration support is made, remains marginal.
The Cultural Container and the Voice
The neuroscience of voice-hearing provides one of the sharper empirical windows into the cultural-container thesis. Functional MRI studies beginning with McGuire et al. (Lancet, 1993) established that auditory verbal hallucinations activate Broca’s area — the same region active during inner speech production — alongside supplementary motor cortex and primary auditory cortex. The corollary discharge model proposes that normally, a predictive signal tags inner speech as self-generated; in voice-hearing, this mechanism fails, so internal verbal productions are experienced as externally sourced. The neurology is real, is replicable, and is consistent across populations.
What varies is everything else. Tanya Luhrmann’s 2015 Stanford study, published in the British Journal of Psychiatry, compared voice-hearing experiences across sixty participants in San Mateo (California), Chennai (India), and Accra (Ghana), all meeting schizophrenia criteria. Seventy percent of American participants reported violent commands from their voices; fifteen percent of Indian and ten percent of Ghanaian participants did. No American participant described the experience as primarily positive; forty-five percent of Indian and fifty percent of Ghanaian participants did. Ghanaian participants overwhelmingly described hearing God speak. Indian participants described playful, familial voices. American participants used diagnostic labels and described the experience as warfare with a broken brain. The finding is precise: cultural frameworks for understanding unusual auditory experience shape the actual affective tone and content of what is heard — the phenomenology itself, including its affective tone and content.
The epidemiological evidence establishes that voice-hearing occurs in six to fifteen percent of the general population (Beavan, Read, and Cartwright, Journal of Mental Health, 2011), the majority of whom never receive a psychiatric diagnosis. The Hearing Voices Movement, founded in the late 1980s by Dutch psychiatrist Marius Romme and researcher Sandra Escher working with voice-hearer Patsy Hage, now operates peer-support networks in over thirty countries. Eleanor Longden, diagnosed with schizophrenia and hospitalized repeatedly in her early twenties, completed a PhD and reframed her voices as dissociated aspects of her own experience. Her 2013 TED talk — viewed over six million times — delivered the core argument: the question psychiatry should ask is what happened to you, not what is wrong with you. The clinical evidence base for the approach remains limited — the multisite Phase II randomized controlled trial (TWV-II, protocol published 2024) has not yet completed — but the epidemiological gap between the symptom’s distribution and the category’s boundaries is a structural feature of the diagnostic apparatus that the movement has made visible.
Trauma, Dissociation, and the Etiological Silence
The correlation between childhood trauma and psychosis is one of the most robust and most systematically neglected findings in the schizophrenia literature. Varese et al. (2012, Schizophrenia Bulletin), in a meta-analysis spanning approximately 79,000 participants across thirty-six studies, found an overall odds ratio of 2.78 for psychosis following childhood adversity, with a population attributable risk of thirty-three percent — meaning that if the causal relationship were removed, roughly one in three psychosis cases would not occur. This figure is comparable to the population attributable risk of cigarette smoking for lung cancer. Read et al. (2005, Acta Psychiatrica Scandinavica) had documented that childhood sexual abuse was reported by twenty-six to forty percent of schizophrenia patients, childhood physical abuse by thirty-nine percent — yet only 0.05 percent of all schizophrenia articles in PsycINFO between 1872 and 2004 mentioned child abuse.
The dissociative model proposes that auditory hallucinations in trauma-exposed individuals represent internalized perpetrator voices — fragmented self-states produced by peritraumatic dissociation that are subsequently experienced as external. Varese et al. (2020, Schizophrenia Bulletin) confirmed the dissociation-psychosis link across twenty-six studies. The type and timing of childhood maltreatment predicted thirty-one percent of variance in dissociative severity in schizophrenia-spectrum patients. The implication is that a substantial fraction of what the diagnostic system classifies as a brain disease may be better understood as a trauma response — one whose treatment requires engagement with the traumatic material rather than pharmacological suppression of the symptoms it produces.
The Long-Term Outcome Problem
Martin Harrow and Thomas Jobe’s twenty-year NIMH-funded longitudinal study at the University of Illinois (the Chicago Followup Study, 139 patients, six assessment points) produced findings the field has been unable to assimilate. More than seventy percent of schizophrenia patients continuously prescribed antipsychotics showed psychotic activity at four or more of six follow-up assessments across twenty years. Patients not prescribed antipsychotics showed significantly less psychotic activity at every assessment point. Harrow addressed the selection-bias objection directly, controlling for initial prognostic indicators and demonstrating that the medication-independent outcome advantage persisted.
Wunderink et al. (2013, JAMA Psychiatry) provided partial randomized confirmation: in a seven-year follow-up of a Dutch RCT, the dose-reduction/discontinuation group achieved a recovery rate of 40.4 percent compared to 17.6 percent in the maintenance-treatment group (OR 3.49, p = .01). The recovery advantage was in functional remission — the ability to work, maintain relationships, live independently — rather than in symptom suppression alone.
The WHO’s International Pilot Study of Schizophrenia (1973), Determinants of Outcome of Severe Mental Disorders (1992), and International Study of Schizophrenia (2000) produced the developing-country advantage finding: patients in India, Nigeria, and Colombia showed substantially better outcomes than patients in the United States, Britain, and Denmark. The Agra (India) site in the ISoS twenty-five-year follow-up showed seventy-seven percent recovered at last assessment. Cohen et al. (2008) challenged the finding’s universality, and Jablensky and Sartorius (2008) responded that the challenge did not overturn the core data, which were collected prospectively under standardized WHO methodology. The developing-country sites shared lower rates of chronic antipsychotic maintenance and the persistence of communal frameworks for understanding and supporting anomalous experience. The world’s most heavily medicalized psychiatric systems do not produce the world’s best schizophrenia outcomes.
Open Dialogue, Soteria, and the Treatment Models That Work
Two treatment models have demonstrated that the standard-of-care approach is not the only approach that produces results. Open Dialogue, developed in Western Lapland, Finland, by Jaakko Seikkula and colleagues beginning in the 1980s, treats first-episode psychosis through immediate family-and-network meetings, minimal or delayed use of neuroleptic medication, and continuity of care with the same treatment team. The nineteen-year follow-up published by Bergström et al. (2018) in Psychiatry Research reported lower disability allowance rates, lower psychiatric medication dispensing, and fewer hospital days in the Open Dialogue cohort compared to national controls. Only thirty-six percent of Open Dialogue patients had used antipsychotic medication at any point during treatment, and seventy-five percent had returned to work or study. The evidence base is not randomized and the Western Lapland cohort may differ from national controls at baseline. The outcomes are nonetheless unmatched by any medication-first protocol in the published literature.
Soteria House, established by Loren Mosher — then chief of NIMH’s Center for Studies of Schizophrenia — in San Jose in April 1971, operated on a similar principle: acute schizophrenic patients were cared for in a small, home-like environment by non-professional staff trained to be with the patient through the psychotic experience without suppressing it, using neuroleptic medication only as a last resort. Bola and Mosher (2003, Journal of Nervous and Mental Disease) reported that Soteria treatment produced better two-year outcomes for patients with newly diagnosed schizophrenia-spectrum psychoses than standard hospital treatment. Mosher resigned from the APA in December 1998 with a public letter: “The major reason for this action is my belief that I am actually resigning from the American Psychopharmacological Association.” Soteria Bern, a Swiss replication operating from 1984, produced “equal and even partly better therapeutic results” with roughly fifty percent lower daily costs (Ciompi and Hoffmann, World Psychiatry, 2004).
Neither Open Dialogue nor Soteria has been scaled. The structural reasons for their marginality are the structural reasons the containment-apparatus analysis identifies: models that reduce medication use contract the pharmaceutical revenue the apparatus depends on, and models that require extended relational engagement with acute patients are more labor-intensive and less scalable within the billing structures the insurance system supports.
The Bioelectric Reading
Within the instrument framework, schizophrenia presents as a coherence problem at the bioelectric level. The kundalini model, the Bentov cardiovascular-oscillation model, and the broader bioelectric-field literature converge on a description in which the nervous system is a tunable resonant system whose coherence state determines the bandwidth of experience accessible to the operator. Ordinary consensus consciousness corresponds to a stable low-coherence configuration. Meditation, contemplative practice, and certain pharmacological interventions shift the system toward higher coherence and expanded bandwidth. Spontaneous, unprepared shifts — kundalini crises, acute psychotic episodes, spiritual emergencies — represent the same transition occurring without adequate structural support.
The neurological evidence partially supports the shared-substrate thesis. Carhart-Harris et al. (2012, PNAS) demonstrated that psilocybin produces its effects through decreased activity and connectivity in the Default Mode Network — the same hub regions that show aberrant connectivity in schizophrenia. Both states involve disruption of the self-referential processing architecture that ordinarily constrains cognition. The 2014 “entropic brain” hypothesis proposed that both psychedelic states and psychotic episodes involve increased neural entropy — a reduction in the brain’s hierarchical order — but via different mechanisms (5-HT2A agonism versus dopamine dysregulation), with different consequences for reality testing (preserved under psilocybin, impaired in psychosis). The overlap is real and neurologically documented. The distinction is in the container.
On this reading, the voice-hearing that the DSM classifies as a first-rank symptom of schizophrenia may in some cases represent reception at frequencies the consensus configuration does not access. The paranoid ideation may in some cases represent pattern-recognition operating on genuine signals the consensus framework does not validate. The qualifier “in some cases” is doing essential work: the reading does not claim that all voice-hearing is reception, that all paranoia is perception, or that all thought disorder is bandwidth expansion. It claims that the diagnostic category, by its design, cannot distinguish the cases where it is from the cases where it is not, and that the treatment protocol applied uniformly across all cases is calibrated to suppress the phenomenology regardless — while producing measurable brain tissue loss in the process.
The Diagnostic Trap
The structural analysis converges with the analysis the targeted-individuals page develops and the containment-apparatus page elaborates. The DSM’s diagnostic framework for schizophrenia functions as a containment device. It absorbs a range of experiences — some pathological, some developmental, some trauma-based, some potentially induced — into a single category whose treatment protocol suppresses the phenomenology without investigating its origin or meaning. The category’s “non-bizarre delusion” criterion, as applied through delusional disorder and shared across the schizophrenia spectrum, means that beliefs which are in principle possible — that one is being monitored, that one’s thoughts are being influenced, that one is receiving communications from non-human sources — receive the same diagnostic treatment as beliefs that are demonstrably false. The system contains no mechanism for evaluating whether the belief is true. It evaluates only whether the belief is normative.
The Soviet deployment of sluggish schizophrenia at the Serbsky Institute made the containment function explicit and deliberate. Snezhnevsky’s diagnostic criteria — “delusion of reformism,” “struggle for truth,” “philosophical intoxication,” “social maladaptation” — described the profile of a coherent political dissident. Vladimir Bukovsky, hospitalized three times and declared “undoubtedly psychopathic” by the Serbsky Institute as recently as 2007, smuggled out psychiatric evaluations and KGB documents that forced the World Psychiatric Association to confront the practice; the Soviet All-Union Society of Psychiatrists withdrew from the WPA in 1983 rather than face expulsion. Jonathan Metzl’s The Protest Psychosis (2010) documented the analogous application of DSM-II schizophrenia criteria to Black civil rights activists in the United States — a domestic deployment of the same structural logic through distributed incentive alignment rather than centralized design.
The consequence at population scale is the one the synthesis page identifies: the diagnostic apparatus functions as a layer of the consciousness-suppression architecture, absorbing the witnesses of operations the apparatus cannot acknowledge and the experiencers of states the apparatus cannot categorize. The MKUltra program and its successors deliberately produced dissociative states whose symptom profiles map directly onto the schizophrenia-spectrum criteria the DSM subsequently codified — a convergence the Shattered Vessel analysis traces through Cameron’s depatterning protocols, the Monarch programming literature, and the clinical presentations Colin Ross documented across two decades of working with survivors. The blackmail architecture depends on the same diagnostic containment: a witness to the operations described in the Epstein files who reports what they saw enters a system calibrated to classify the report as persecutory delusion before its content can be evaluated. The diagnostic category, the programming apparatus, and the blackmail architecture are three faces of a single operational structure — and the standard-of-care treatment protocol produces, in addition to its diagnostic containment function, measurable brain volume reduction, receptor-remodeling chronification, and outcomes that the developing world, with fewer resources and more antipsychotic restraint, consistently surpasses.
References
Beavan, Vivien, John Read, and Claire Cartwright. “The Prevalence of Voice-Hearers in the General Population: A Literature Review.” Journal of Mental Health, 20(3), 2011, pp. 281–292.
Bergström, Tomi, et al. “The Family-Oriented Open Dialogue Approach in the Treatment of First-Episode Psychosis: Nineteen-Year Outcomes.” Psychiatry Research, 270, 2018, pp. 168–175.
Bleuler, Eugen. Dementia Praecox or the Group of Schizophrenias. 1911. Trans. Joseph Zinkin. International Universities Press, 1950.
Bola, John R., and Loren R. Mosher. “Treatment of Acute Psychosis Without Neuroleptics: Two-Year Outcomes from the Soteria Project.” Journal of Nervous and Mental Disease, 191(4), 2003, pp. 219–229.
Carhart-Harris, Robin L., et al. “Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin.” PNAS, 109(6), 2012, pp. 2138–2143.
Ciompi, Luc, and Holger Hoffmann. “Soteria Berne: An Innovative Milieu Therapeutic Approach to Acute Schizophrenia Based on the Concept of Affect-Logic.” World Psychiatry, 3(3), 2004, pp. 140–146.
Greyson, Bruce. “The Physio-Kundalini Syndrome and Mental Illness.” Journal of Transpersonal Psychology, 25(1), 1993, pp. 43–58.
Harrow, Martin, Thomas H. Jobe, and Rangaswamy N. Faull. “Does Treatment of Schizophrenia with Antipsychotic Medications Eliminate or Reduce Psychosis?” Psychological Medicine, 44(14), 2014, pp. 3007–3016.
Ho, Beng-Choon, Nancy C. Andreasen, Steven Ziebell, Ronald Pierson, and Vincent Magnotta. “Long-Term Antipsychotic Treatment and Brain Volumes.” Archives of General Psychiatry, 68(2), 2011, pp. 128–137.
Howes, Oliver D., and Shitij Kapur. “The Dopamine Hypothesis of Schizophrenia: Version III — The Final Common Pathway.” Schizophrenia Bulletin, 35(3), 2009, pp. 549–562.
Jablensky, Assen. “The Diagnostic Concept of Schizophrenia: Its History, Evolution, and Future Prospects.” Dialogues in Clinical Neuroscience, 12(3), 2010, pp. 271–287.
Luhrmann, Tanya M., R. Padmavati, H. Tharoor, and A. Osei. “Differences in Voice-Hearing Experiences of People with Psychosis in the USA, India, and Ghana.” British Journal of Psychiatry, 206, 2015, pp. 41–44.
Metzl, Jonathan. The Protest Psychosis: How Schizophrenia Became a Black Disease. Beacon Press, 2010.
Perry, John Weir. The Far Side of Madness. Prentice-Hall, 1974.
Read, John, Jan van Os, Anthony P. Morrison, and Colin A. Ross. “Childhood Trauma, Psychosis and Schizophrenia: A Literature Review with Theoretical and Clinical Implications.” Acta Psychiatrica Scandinavica, 112(5), 2005, pp. 330–350.
Sannella, Lee. Kundalini: Psychosis or Transcendence? H.S. Dakin, 1976.
Silverman, Julian. “Shamans and Acute Schizophrenia.” American Anthropologist, 69(1), 1967, pp. 21–31.
Varese, Filippo, et al. “Childhood Adversities Increase the Risk of Psychosis: A Meta-Analysis of Patient-Control, Prospective- and Cross-Sectional Cohort Studies.” Schizophrenia Bulletin, 38(4), 2012, pp. 661–671.
Whitaker, Robert. Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. Crown, 2010.
Wunderink, Lex, et al. “Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy.” JAMA Psychiatry, 70(9), 2013, pp. 913–920.